- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 27 Jan 2026 | 20 Jan 2026 |
| Quarterly Results Financial Result Quarter ended on December 31, 2025 Outcome of Board Meeting held on January 27, 2026 (As Per BSE Announcement Dated on: 27/01/2026) | ||
| Board Meeting | 15 Dec 2025 | 15 Dec 2025 |
| Outcome of Board meeting held on December 15, 2025 | ||
| Board Meeting | 17 Oct 2025 | 10 Oct 2025 |
| RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2025 inter alia to consider and approve RPG Life Sciences Limited informed that the meeting of the Board of Directors of the Company is scheduled on 17/10/2025 to consider and approve Unaudited Financial Results for the quarter and half year ended September 30 2025. Financial Result Outcome of Board Meeting held on October 17, 2025 (As Per Bse Announcement dated on 17/10/2025) | ||
| Board Meeting | 25 Jul 2025 | 18 Jul 2025 |
| RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2025 inter alia to consider and approve Board Meeting Intimation to Consider and Approve Unaudited Financial Results for the quarter Ended June 30 2025 In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Friday, July 25, 2025 inter-alia considered and unanimously approved the following agenda items: 1. Unaudited Financial Results: The Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Revision in the Policy for Determination of Materiality of Events: Revision in the policy for Determination of Materiality of Events in accordance with the amended SEBI (Listing Obligations and Disclosure Requirements), 2015. The aforesaid amended policy shall be made available on the Companys website at www.rpglifesciences.com_policies Unaudited financial result for the quarter ended on June 30, 2025 Pursuant to Regulation 30 of the SEBI LODR, 2015 we wish to inform you that, on the recommendation of NRC committee and Board approved appointment of Mr. Deepak Shukla as Chief Executive -API Business in capacity of SMP wef from July 28, 2025 (As per BSE Announcement Dated on 25/07/2025) | ||
| Board Meeting | 28 Apr 2025 | 21 Apr 2025 |
| RPG Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2025 inter alia to consider and approve Pursuant to regulation 29 of the SEBI LODR 2015 this is to inform you that a meeting of the board of directors of the company is scheduled on Monday April 28 2025 inter alia to- 1. Consider and approve the Audited Financial Results for the quarter and financial year ended March 31 2025. 2. Recommend dividend if any on Equity Shares of the Company for the financial year ended March 31 2025 Further pursuant to the Code of Fair Disclosure Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Insiders of the Company and the SEBI (Prohibition of Insider Trading) Regulations 2015 the Trading Window for dealing in Securities of the Company by Designated Persons and their immediate relatives is closed from April 1 2025 and will continue to remain closed till 48 hours after declaration of results on April 28 2025. Audited Financial Result for the Quarter and year ended on March 31, 2025 Recommended of final dividend of Rs. 20 (Rupees Twenty only) per equity share (250% on the face value of Rs.8 each) and additionally a special dividend of Rs. 4 (Rupees Four only) per equity share (50% on the face value of Rs. 8 each) on account of significant exceptional profit on assignment of land for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement dated on 28.04.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
